Expression of human melanocortin 4 receptor in Saccharomyces cerevisiae

Central European Journal of Biology

Volumn 6, Issue 2, 2011, Pages 167-175

  Ignatovica, Vita ^a   Petrovska, Ramona ^a   Fridmanis, Davids ^a   Klovins, Janis ^a  

^a LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

Author keywords

functional screens; G protein coupled receptors; melanocortin receptors; Saccharomyces cerevisiae

Indexed keywords

MAMMALIA; SACCHAROMYCES CEREVISIAE;

EID: 79651471506     PISSN: 1895104X     EISSN: 16443632     Source Type: Journal    
DOI: 10.2478/s11535-011-0002-3     Document Type: Article

References (40)

1. Chhajlani V., Muceniece R., Wikberg J. E., Molecular cloning of a novel human melanocortin receptor, Biochem. Biophys. Res. Commun., 1993, 195, 866-873.
2. Gantz I., Konda Y., Tashiro T., Shimoto Y., Miwa H., Munzert G., et al. Molecular cloning of a novel melanocortin receptor, J. Biol. Chem., 1993, 268, 8246-8250.
3. Gantz I., Miwa H., Konda Y., Shimoto Y., Tashiro T., Watson S. J., et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor, J. Biol. Chem., 1993, 268, 15174-15179.
4. Mountjoy K. G., Robbins L. S., Mortrud M. T., Cone R. D., The cloning of a family of genes that encode the melanocortin receptors, Science, 1992, 257, 1248-1251.
5. Crine P., Gossard F., Seidah N. G., Blanchette L., Lis M., Chretien M., Concomitant synthesis of betaendorphin and alpha-melanotropin from two forms of pro-opiomelanocortin in the rat pars intermedia, Proc. Natl. Acad. Sci. USA, 1979, 76, 5085-5089.
6. Hadley M. E., Haskell-Luevano C., The proopiomelanocortin system, Ann. N Y Acad. Sci., 1999, 885, 1-21.
7. Mains R. E., Eipper B. A., Synthesis and secretion of corticotropins, melanotropins, and endorphins by rat intermediate pituitary cells, J. Biol. Chem., 1979, 254, 7885-7894.
8. Gantz I., Fong T. M., The melanocortin system, Am. J. Physiol. Endocrinol. Metab., 2003, 284, E468-E474.
9. Gantz I., Shimoto Y., Konda Y., Miwa H., Dickinson C. J., Yamada T., Molecular cloning, expression, and characterization of a fifth melanocortin receptor, Biochem. Biophys. Res. Commun., 1994, 200, 1214-1220.
10. Mountjoy K. G., Mortrud M. T., Low M. J., Simerly R. B., Cone R. D., Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain, Mol. Endocrinol., 1994, 8, 1298-1308.
11. Pritchard L. E., Turnbull A. V., White A., Proopiomelanocortin processing in the hypothalamus: impact on melanocortin signalling and obesity, J. Endocrinol., 2002, 172, 411-421.
12. Chhajlani V., Distribution of cDNA for melanocortin receptor subtypes in human tissues, Biochem. Mol. Biol. Int., 1996, 38, 73-80.
13. Konturek P. C., Konturek J. W., Czesnikiewicz-Guzik M., Brzozowski T., Sito E., Konturek S. J., Neurohormonal control of food intake: basic mechanisms and clinical implications, J. Physiol. Pharmacol., 2005, 56, 5-25.
14. Williams G., Bing C., Cai X. J., Harrold J. A., King P. J., Liu X. H., The hypothalamus and the control of energy homeostasis: different circuits, different purposes, Physiol. Behav., 2001, 74, 683-701.
15. Huszar D., Lynch C. A., Fairchild-Huntress V., Dunmore J. H., Fang Q., Berkemeier L. R., et al., Targeted disruption of the melanocortin-4 receptor results in obesity in mice, Cell, 1997, 88, 131-141.
16. Butler A. A., The melanocortin system and energy balance, Peptides, 2006, 27, 281-290.
17. Chen A. S., Marsh D. J., Trumbauer M. E., Frazier E. G., Guan X. M., Yu H., et al., Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass, Nat. Genet., 2000, 26, 97-102.
18. Fleck B. A., Chen C., Yang W., Huntley R., Markison S., Nickolls S. A., et al., Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor, Biochemistry, 2005, 44, 14494-14508.
19. Hogan K., Peluso S., Gould S., Parsons I., Ryan D., Wu L., et al. Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3. 28(125), I3. 32(129), and I7. 42(291) is critical for receptor activation, J. Med. Chem., 2006, 49, 911-922.
20. Nickolls S. A., Cismowski M. I., Wang X., Wolff M., Conlon P. J., Maki R. A., Molecular determinants of melanocortin 4 receptor ligand binding and MC4/MC3 receptor selectivity, J. Pharmacol. Exp. Ther., 2003, 304, 1217-1227.
21. Nickolls S. A., Fleck B., Hoare S. R., Maki R. A., Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states, J. Pharmacol. Exp. Ther., 2005, 313, 1281-1288.
22. Oosterom J., Nijenhuis W. A., Schaaper W. M., Slootstra J., Meloen R. H., Gispen W. H., et al., Conformation of the core sequence in melanocortin peptides directs selectivity for the melanocortin MC3 and MC4 receptors, J. Biol. Chem., 1999, 274, 16853-16860.
23. Wilczynski A., Wang X. S., Joseph C. G., Xiang Z., Bauzo R. M., Scott J. W., et al., Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands, J. Med. Chem., 2004, 47, 2194-2207.
24. Yang Y. K., Fong T. M., Dickinson C. J., Mao C., Li J. Y., Tota M. R., et al., Molecular determinants of ligand binding to the human melanocortin-4 receptor, Biochemistry, 2000, 39, 14900-14911.
25. Haskell-Luevano C., Cone R. D., Monck E. K., Wan Y. P., Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants, Biochemistry, 2001, 40, 6164-6179.
26. Baranski T. J., Herzmark P., Lichtarge O., Gerber B. O., Trueheart J., Meng E. C., et al., C5a receptor activation. Genetic identification of critical residues in four transmembrane helices, J. Biol. Chem., 1999, 274, 15757-15765.
27. Beukers M. W., van Oppenraaij J., van der Hoorn P. P., Blad C. C., den Dulk H., Brouwer J., et al., Random mutagenesis of the human adenosine A2B receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations, Mol. Pharmacol., 2004, 65, 702-710.
28. Erlenbach I., Kostenis E., Schmidt C., Serradeil-Le Gal C., Raufaste D., Dumont M. E., et al., Single amino acid substitutions and deletions that alter the G protein coupling properties of the V2 vasopressin receptor identified in yeast by receptor random mutagenesis, J. Biol. Chem., 2001, 276, 29382-29392.
29. Miret J. J., Rakhilina L., Silverman L., Oehlen B., Functional expression of heteromeric calcitonin gene-related peptide and adrenomedullin receptors in yeast, J. Biol. Chem., 2002, 277, 6881-6887.
30. Pausch M. H., Lai M., Tseng E., Paulsen J., Bates B., Kwak S., Functional expression of human and mouse P2Y12 receptors in Saccharomyces cerevisiae, Biochem. Biophys. Res. Commun., 2004, 324, 171-177.
31. Schmidt C., Li B., Bloodworth L., Erlenbach I., Zeng F. Y., Wess J., Random mutagenesis of the M3 muscarinic acetylcholine receptor expressed in yeast. Identification of point mutations that "silence" a constitutively active mutant M3 receptor and greatly impair receptor/G protein coupling, J. Biol. Chem., 2003, 278, 30248-30260.
32. Beukers M. W., Ijzerman A. P., Techniques: how to boost GPCR mutagenesis studies using yeast, Trends Pharmacol. Sci., 2005, 26, 533-539.
33. Pausch M. H., G-protein-coupled receptors in Saccharomyces cerevisiae: high-throughput screening assays for drug discovery, Trends Biotechnol., 1997, 15, 487-494.
34. Mumberg D., Muller R., Funk M., Regulatable promoters of Saccharomyces cerevisiae: comparison of transcriptional activity and their use for heterologous expression, Nucl. Acids Res., 1994, 22, 5767-5768.
35. Adan R. A., Szklarczyk A. W., Oosterom J., Brakkee J. H., Nijenhuis W. A., Schaaper W. M., et al., Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat, Eur. J. Pharmacol., 1999, 378, 249-258.
36. Bosch M. P., Campos F., Niubo I., Rosell G., Diaz J. L., Brea J., et al., Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor, J. Med. Chem., 2004, 47, 4041-4053.
37. Sebhat I. K., Martin W. J., Ye Z., Barakat K., Mosley R. T., Johnston D. B., et al., Design and pharmacology of N-[(3R)-1, 2, 3, 4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1, 2, 4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist, J. Med. Chem., 2002, 45, 4589-4593.
38. Geva A., Lassere T. B., Lichtarge O., Pollitt S. K., Baranski T. J., Genetic mapping of the human C5a receptor. Identification of transmembrane amino acids critical for receptor function, J. Biol. Chem., 2000, 275, 35393-35401.
39. Armbruster B. N., Li X., Pausch M. H., Herlitze S., Roth B. L., Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand, Proc. Natl. Acad. Sci. USA, 2007, 104, 5163-5168.
40. Srinivasan S., Lubrano-Berthelier C., Govaerts C., Picard F., Santiago P., Conklin B. R., et al., Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans, J. Clin. Invest., 2004, 114, 1158-1164.